Last chance to take action! 

View this email in your browser ([link removed])
Hi
John,
There are only a few more hours to submit your public comment to the FDA ([link removed]) telling them to center patient voices throughout the drug development process! Check out our email below for more information.

In our most recent blog post ([link removed]) , BCAction Community Leader, Marie Garlock states, "To date, the FDA’s stated commitments to patient-centeredness don’t have any real enforceability when it comes to how clinical trials are run, because the FDA is not yet including any patients in working groups and advisory boards at the investigational new drug (IND) stage when trial design standards are decided."

Take action now and leave your public comment using our easy tool. ([link removed])

Jayla Burton
Program Officer
[link removed]
Hi
John,
The Food and Drug Administration’s role is to protect public health by ensuring safety and efficacy of drugs and medical devices, including those used to treat breast cancer. The drug approval process should put patients before the profits of manufacturers and pharmaceutical companies, and new breast cancer therapies should be more effective, less toxic, and less expensive than current therapies.

Now is the time to act—public comments are open until September 11. Tell the FDA that ensuring the safety and efficacy of drugs and devices starts with centering patient voices! ([link removed])

[link removed]

The FDA approval process has been chipped away at over the years and is now a one-sided process that puts industry over patient health and safety. As a result, in their own assessment of drug safety and efficacy, they over-promote positive outcomes and are not transparent about the negative effects caused by a drug or device. Rather than a closed-door process that benefits industry and drug makers alone, the FDA must include patient and advocate perspectives early and throughout drug development.

Take action before September 11th to submit public comment to the FDA telling them to include and uplift breast cancer patient perspectives! ([link removed])

We've made it easy for you to submit your public comments to the FDA. Customize your comment and tell the FDA why this matters to you!

In solidarity,

Tibby Reas Hinderlie
Communications Association
[link removed]

============================================================
** Twitter ([link removed])
** Facebook ([link removed])
** Website ([link removed])
** YouTube ([link removed])
** Email (mailto:[email protected])
Copyright ©2020 Breast Cancer Action, All rights reserved.

Our mailing address is:
548 Market St, PMB 17179 San Francisco, California 94104-5401

Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.